Rebates Redux: Medicare Drug Rebates Next?
This article was originally published in RPM Report
Drug prices have lost their headline appeal. That has got to be a relief to pharma execs who have pipeline problems and patent expirations to deal with and don't need to be worried about bad publicity egging on Congress to price-control schemes. But there are new threats to drug prices brewing - and one of them is industry's old nemesis: government rebates.
You may also be interested in...
Rep. Waxman Can Move Follow-On Biologics As New Commerce Chairman
Follow-on biologics legislation will be crafted and brokered in the House by new Energy and Commerce Committee Chairman, Henry Waxman
Rep. Waxman Can Move Follow-On Biologics In New Role As Energy and Commerce Chairman
Victory over "Dean of the House" Dingell puts Waxman in the driver's seat to steer major legislation impacting the drug industry.
Adding Part D Protected Classes Could Cut Rebates 8%-31% – AMCP Study
Manufacturer rebates to Medicare Part D plans for diabetes therapies could be reduced by 8 percent if coverage of "substantially" all drugs in that category were required, according to a study commissioned by the Academy of Managed Care Pharmacy